ArticleFrontiers in oncology2026
Case report: Systemic T-DXd and bevacizumab plus local therapy prolongs survival in breast cancer leptomeningeal metastasis: a case series and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastasis from breast cancer has a low incidence but an extremely poor prognosis. With the development of antitumor therapies, the survival of patients with metastatic breast cancer has been significantly prolonged. However, due to the presence of the blood-brain barrier, intracranial metastasis has become increasingly prominent, and the incidence of leptomeningeal metastasis is gradually rising, warranting greater attention and improvement. Currently, there is a lack of effective treatment options for leptomeningeal metastasis, and no unified diagnostic or therapeutic standards exist. This case series reports seven breast cancer patients with leptomeningeal metastasis who received trastuzumab deruxtecan combined with whole-brain radiotherapy; four of them also received bevacizumab and intrathecal chemotherapy. In these four patients, the addition of bevacizumab and intrathecal therapy was associated with rapid alleviation of central nervous system symptoms and a numerically longer overall survival (9.0-20.2 months) compared with historical data. No severe or fatal adverse events were observed. Additionally, through a review of the literature, we summarize the current status, diagnosis, treatment, prognosis, and potential future directions of leptomeningeal metastasis from breast cancer, aiming to provide reference for the management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.